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Abstract
Background: Atrial fibrillation (AF) affects up to 10% of people aged ≥65 years, yet a third of all cases 
remain undetected. Practice- based pharmacists are in an ideal position to facilitate opportunistic AF 
screening, while increasing general practice capacity at a time of workforce crisis.
Aim: To explore the perspectives of three stakeholder groups involved in the ‘Pharmacists Detecting 
Atrial Fibrillation’ (PDAF) study to elucidate the facilitators and barriers to pharmacist- led AF screening 
in general practice.
Design & setting: A qualitative study took place, comprising homogeneous focus groups with 
stakeholders in Kent, UK.
Method: The stakeholder groups — patients, general practice staff (GPS), and clinical pharmacists 
(CPs) — were recruited using convenience sampling. Audio- recordings were transcribed verbatim and 
analysed using a deductive Theoretical Domains Framework (TDF) approach.
Results: Twenty- five patients, four pharmacists, and nine practice staff participated in six focus 
groups. Three main themes were identified: knowledge and awareness; prioritisation of resources; 
and environmental considerations. The public’s lack of awareness of AF- related risks and pharmacist- 
led screening services was highlighted. Practice- based pharmacists were perceived as an underutilised 
educational resource which, together with novel electrocardiogram devices, enabled convenient 
access to screening while reducing GPs’ workload. Participants agreed that AF screening should be 
incorporated into personalised health checks and at- risk groups should be prioritised, such as care 
home residents. Patients favoured the general practice environment over the community pharmacy 
where concerns of privacy, staffing, and commercialisation were raised.
Conclusion: The findings of this study support the introduction of pharmacist- led AF screening 
programmes in general practice surgeries. Commissioners should consider the added value of utilising 
CPs and focus on the delivery of AF screening within an integrated service.
How this fits in
AF is a major cause of preventable stroke, which, despite international recommendations for 
opportunistic screening, remains widely undiagnosed. Primary care network integration of practice- 
based pharmacists provides a multidisciplinary option for the development of the national AF 
screening programme during the time of increased general practice workload pressures. This 
qualitative evaluation of the multi- site PDAF study in Kent (UK) offers an insight into key enablers and 
barriers to service development from the perspectives of patients, pharmacists, and practice staff. In 
the absence of published literature pertaining to pharmacist- led AF screening in general practice, the 
Savickas V et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101042
 
 2 of 13
Research
findings presented here provide the necessary evidence in support of the service, while discussing its 
positive impact for patients and clinicians alike.
Introduction
AF affects up to one in 10 people aged ≥65 years in England; although, 30% of all cases remain 
undiagnosed.1 Individuals with untreated AF display a five- fold greater risk of cardioembolic 
stroke, resulting in a preventable annual NHS bill of £2.2 billion.2,3 Opportunistic AF screening is 
recommended by both international guidelines and a 2018 white paper,4,5 but is not supported by UK 
national guidance.6,7 Despite this discordance, the government has set a target to detect 85% of AF 
cases by 2029.8
To facilitate AF detection, >6000 mobile single- lead electrocardiogram (ECG) devices have been 
distributed to primary care settings.9 Such devices offer a rapid, convenient, and highly accurate 
means of AF detection.10–14 However, service pressures within general practice have curtailed the 
implementation of screening services15,16 and encouraged commissioners to search for alternative 
multidisciplinary models of care.17,18 The feasibility of pharmacist- led AF screening in community 
pharmacies has been investigated.19,20 Despite promising findings, real- life implementation of the 
AF screening service in this setting is limited by multiple barriers, including inadequate follow- up.21,22
Integration of pharmacists within surgeries may overcome these hurdles and simultaneously 
increase general practice capacity.23 Launched in 2015, the ‘Clinical Pharmacists in General Practice’ 
pilot created >1500 pharmacist vacancies in general practice surgeries to alleviate GP workload by 
reviewing patients with long- term illnesses or managing common ailments.24 Primary care networks 
plan to build on the success of this pilot by employing at least one clinical pharmacist (CP) per 
practice25 by 2024 and their roles could include routine screening services.
PDAF was a multi- site study in UK general practice surgeries, which determined the impact of CP- 
led AF screening using either conventional pulse palpation or novel single- lead ECG devices during the 
influenza vaccination season (reported elsewhere).26,27 This study constitutes a qualitative stakeholder 
evaluation of the PDAF intervention,28 and identifies facilitators and barriers to its implementation 
focusing on the novel role of pharmacists in general practice.
Method
Focus groups were conducted to ascertain the perspectives of three stakeholder groups: patients, 
GPS, and CPs.26 This method is commonly used in qualitative research and generates rich data to 
shape complex healthcare interventions.29,30 Stakeholders were recruited using convenience sampling, 
and all interested individuals were invited to participate.
CPs provided all PDAF participants with an invitation and information leaflet for the focus group 
regardless of their AF screening result or demographic characteristics. All CPs involved in the PDAF 
initiative were emailed an invitation to participate at the end of the study by the research team. The 
gatekeeper at each participating surgery distributed internal email invitations to all GPS. Written 
informed consent was obtained.
Semi- structured topic guides for each participant group contained open- ended questions and 
were developed from the literature.13,21 All interviews were audio- recorded, transcribed verbatim, 
coded, and analysed by one research team member. Another researcher independently verified the 
accuracy of transcription and rigour of data analysis. Both researchers were registered pharmacists 
and maintained a reflexive account to acknowledge the possible influence of their professional 
background.31
Patient demographics were analysed using SPSS (version 25). Qualitative data were analysed in 
NVivo (version 12) using the deductive TDF approach, as detailed in Figure 1.32,33 TDF domains most 
likely to influence the service proposed were selected using the criteria adapted from Islam et al.34 The 
major themes and sub- themes within these domains were selected for final analysis of key facilitators 
and barriers. Deviant case analysis was performed to ensure that perspectives that diverged from 
dominant trends were not overlooked.35
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Results
Twenty- five patients attended four 80–90- minute 
focus group discussions in January 2018 
and February 2019 (5–7 patients per group). 
Participants from all four practices involved in the 
PDAF study were represented and were slightly 
younger than the main cohort (Table  1). Most 
patients were aware of AF screening taking place 
and pre- booked their appointments (68%); others 
were screened before or after their influenza 
vaccination, or at another appointment (32%).
Four CPs and nine GPS participated in two 
separate 40- minute focus groups. CPs had 
6–15 years of professional experience, and 
two of them were male. All GPS were female 
and worked at one of the four surgeries: three 
were office support staff, two receptionists, and 
Figure 1 Three- step approach to data analysis based on the Theoretical Domains Framework (TDF) and analytical strategy adapted from Atkins et al32 
and Islam et al34
Table 1 Comparison of focus group and PDAF 
study participants’ demographic characteristics 
(n = 25 and n = 604, respectively). Continuous 
variables are expressed as a median (interquar-
tile range). Categorical variables are expressed 





Age, years 71 (68 to 73)a 73 (69 to 78)a
Male 13 (52.0) 258 (42.7)
Ethnic group
White British 23 (92.0) 585 (96.9)
Other 2 (8.0) 19 (3.1)
aP = 0.023 as determined by Wilcoxon’s signed rank 
test.
PDAF = Pharmacists Detecting Atrial Fibrillation.
Savickas V et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101042
 
 4 of 13
Research
the remainder a research administrator, a prescribing technician, a student nurse, and a healthcare 
assistant.
Themes from coding and preliminary analysis are summarised in Figure 2. Subsequent analysis 
identified three overarching themes: knowledge and awareness; prioritisation of resources; and 
environmental considerations. These themes were mapped onto five most relevant TDF domains 
(Table 2).
Knowledge and awareness
awareness of aF and screening
Patients and GPS admitted that they did not know much about AF- related risks prior to the screening 
initiative, despite some suffering from other cardiovascular conditions:
‘Although I’ve had hypertension for 25 years … I wasn’t particularly aware of this other than 
from our friend who had irregular heart beat, well I thought it’s just an irregular heart beat, 
similar things.’ (PT9)
Two patients with a pre- study diagnosis of AF emphasised the need to educate the public about 
the condition and related risks:
‘Do people know? I didn’t know anything about atrial fibrillation until the age of 63. We all know 
about breast cancer and colon cancer, AIDS and all kinds of other things where there’s been 
promotion for people that need testing.’ (PT7)
Figure 2 A Venn diagram depicting the TDF domains most likely to influence the facilitators and barriers to 
service development and implementation identified during the coding and preliminary analysis. The most relevant 
domains for each stakeholder group were selected using the criteria by Islam et al34 (n = 25 for patients, n = 9 for 
general practice staff, and n = 4 for pharmacists).
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Patients were motivated to attend owing to personal risk factors, such as older age, family history 
of heart disease, or social responsibility:
‘We need to take pressure away from hospitals and, as I said earlier, prevention is better than 
cure. If you know you’ve got a problem, you can have it treated at point A. You’re not going to 
end up in point E where you’re gonna spend three or four weeks in hospital.’ (PT19)
All stakeholders agreed that the PDAF study was biased towards proactive, lower- risk patients and 
that the asymptomatic nature of AF was a particular challenge in engaging less motivated individuals.
‘People who don’t attend the flu vaccine are probably ones who are more at risk because they’re 
not looking after their health.’ (CP4)
Patients and staff proposed ways to raise public awareness of AF and improve uptake of screening, 
including patient- friendly posters, websites, text messages, emails, mobile- phone applications, AF 
awareness campaigns, and TV and/or radio programmes:
'Website, leaflets, through to the maybe at- risk patients or things like that.’ (GPS5)
‘Could we put up posters of Age Concern? In our surgery could we send texts?’ (GPS9)
Role of pharmacists
Both patients and GPS felt that the public often perceived pharmacists as 'shop assistants' rather than 
healthcare professionals (HCPs) who can play a role in public health services:
‘Then people need to be made aware of what the pharmacists can do. Because as far as I’m 
concerned, the pharmacist is just a guy in a local shop and I go seem him if I’ve got a headache 
or a cold or something like that.’ (PT3)
Table 2 Key facilitators and barriers to atrial fibrillation screening service proposed mapped against the most relevant TDF domains 
(n = 25 for patients, n = 9 for GPS and n = 4 for pharmacists).
TDF domain(s) Facilitators
Stakeholder 
group(s) Barriers Stakeholder group(s)
Environmental context 
and resources
Space and established general practice 
infrastructure
All Busy clinic environment All
Advantages of single- lead ECG Patients and 
pharmacists
Accessibility of community 
pharmacy
Pharmacists and patients
Presence of HCP Patients Service costs and resources Patients and GPS
Variation in practice culture and 
poor service integration
Pharmacists
Variable access to care Patients
Logistics of same- day screening
Goals Prioritisation of at- risk groups All Screening led by other HCPs Pharmacists and patients
Flexible choice of appointment Patients and GPS Self- testing technology Patients
Engagement of stakeholders Pharmacists
Social or professional 
role and identity
Utilisation of pharmacists’ skills All Misconceptions about pharmacists Patients and GPS
Development of pharmacists’ roles Pharmacists Unconventional role of pharmacists Pharmacists
Knowledge and social 
influences*
Knowledge and awareness Patients and GPS Getting used to novel screening Patients
Staff inclusion in service provision GPS Lack of communication with staff GPS
*N.b. Knowledge and social influences are two separate domains but are combined in this table because some facilitators/barriers mapped onto both 
domains.
ECG = electrocardiogram. GPS = general practice staff. HCP = healthcare professional.
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A few patients and staff expressed doubts regarding pharmacists’ clinical abilities. Engagement in 
AF screening appeared to modify patients’ views about CPs, and several patients pointed out that 
public awareness of pharmacist- led services could be raised by carrying out similar initiatives:
'And it’s only recently that it’s been done with you, that you actually recognise that a pharmacist 
is a very, very skilled and trained person and has got an immense knowledge of a wide range of 
problems …’ (PT14)
Prioritisation of resources
effective use of novel technology
Patients were fascinated by the mobile technology, which made the AF screening process quick, non- 
invasive, and painless. They were intrigued by the live recording of their ECG and appreciated the 
presence of the pharmacist, who provided them with immediate reassurance:
‘The guy that was talking to us said, “do you realise that your heart works in more than just 
one way?” and when our recording came out with all these various times, and saying, “this is 
this part of it working, this is this…” and that fascinated me the fact you go along usually and 
someone says you know, “right, here’s your heart and it goes bleep, yeah, it’s all fine.”’ (PT14)
In turn, CPs reported patients’ interest in the technology and emphasised the convenience of 
having a 'pocket' device with them at all times. They expressed a strong 'faith' in the device, which in 
addition to AF, helped identify other suspected hearth rhythm disorders and was more reliable than 
conventional pulse palpation:
‘I just found there was so much variability that actually that’s why I did like the device was 
because having taken a lot of pulses now, you can see how things could get missed if you just 
rely on pulses.’ (CP4)
Considering the device’s simplicity, several patients proposed self- testing for AF, questioning 
whether or not a HCP was required. However, most remained cautious towards the use of technology 
owing to fear of misdiagnosis:
‘The danger of doing things in that mind is that you might think you’ve got something very 
wrong and panic and so on because of what you consider your findings on your computer.’ 
(PT15)
service costs and resources
Patients generally considered opportunistic AF screening to be worthwhile as part of the broader 
preventive healthcare agenda. Some were more sceptical, wondering if the screening programme 
would result in substantial savings when compared with usual care:
‘If you’re notifying people, radio, TV, whatever, and you’re hoping to identify lots of people who 
are potentially gonna get or have got AF, and then you can start giving them pills from a certain 
point, how does that stack up against the cost if you do nothing and then they go into AF and 
need to be hospitalised?’ (PT6)
Some of these concerns were mentioned by GPS who identified equipment, staff, and follow- up 
costs as barriers:
'If it’s funded, then probably [laughs]. But I don’t know if it wasn’t because like they were 
saying all the equipment is going to cost money …’ (GPS1)
'As well if the pharmacist were provided …’ (GPS3)
‘And the time because you would have to follow them up so it would be a lot more for you, 
wouldn’t it?’ (GPS6)
Patients and surgery staff also reflected on the extra resources associated with same- day pre- 
or post- influenza vaccination screening, such as the waiting time or unplanned parking costs. For 
others, the efficiency and convenience of same- day screening seemed to counteract the poor use 
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of resources. Three interviewees proposed a flexible system, giving individuals the option to wait or 
return for an appointment:
‘Some patients are not gonna come back, you gonna need to grab them when they’re here. 
Unfortunately, that’s the way they are. But other people will be prepared to come back to a 
clinic.’ (GPS3)
Aside from time and monetary considerations, CPs and GPS touched on the benefits of stakeholder 
engagement in AF screening, focusing on GPs, clinical specialists, commissioners, allied HCPs, and 
administrative staff:
‘But it works better when the GPs in the vaccination clinic said this would be a good thing done, 
get it done […] If the GPs didn’t back it up then there was less up take.’ (CP4)
Targeting high-risk groups
Numerous patients and pharmacists suggested targeting individuals for screening in public locations, 
such as supermarkets, gyms or the high street:
‘… we used to stand there and drag the people off the street to have their blood pressure 
checked and some of them were an immediate, “Tom, we have to send you to hospital.”’ (PT11)
Pharmacists and GPS spoke about patients who were housebound or care home residents who had 
limited access to health care, despite being at- risk of cardiovascular disease:
‘Obviously, you’re missing all of the housebound patients as well because we don’t go to 
search in care homes, there’s gonna be actually quite a few in care homes.’ (GPS6)
‘They’re not going anywhere so you’ve got a captive audience.’ (CP3)
Multiple patients thought that the eligibility criteria for AF screening should be broadened to 
include other at- risk groups, for instance, overweight individuals. Pharmacists and GPS suggested that 
AF screening could be extended to patients with long- term illnesses such as diabetes or hypertension. 
The outcome of such discussions was the concept of a personalised health screening plan repeatedly 
referred to by patients as the ‘MOT’ (a reference to the annual UK Ministry of Transport check for 
motor vehicles):
‘If your car is over a certain age and every year you go and have an MOT, then possibly we ought 
to be doing, thinking the same way …’ (PT14)
Pharmacists as underutilised resource
GPS and patients viewed pharmacists as highly qualified practitioners whose expertise was underutilised 
at the time of increased service pressures, highlighting the juxtaposition of this viewpoint with the 
widely held perception of pharmacists as 'shopkeepers'. Patients believed that additional pharmacist- 
led services would reduce GP workload and may improve their access to health care regardless of 
whether these were delivered in community pharmacies or GP surgeries:
‘The clinicians say they are terribly overstretched and anything that you can do … And you 
are not stupid, you are well- qualified people who have a good understanding certainly of 
pharmacology and medicines. Very well- qualified to do such things.’ (PT1)
As members of the multidisciplinary team, pharmacists were identified as the HCPs to bridge the 
knowledge gap between patients and doctors:
‘I think, they kind of act as the middle ground between the GPs and the patients.’ (GPS6)
Reflecting on trust placed in them by patients and staff, pharmacists displayed optimism about the 
AF screening role, particularly their ability to communicate test results and educate patients. These 
skills seemed to be the distinguishing point between the pharmacists and technical personnel:
Savickas V et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101042
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‘The feedback I got instantly from people was like, “oh wow that’s brilliant you know. That’s 
really given me some extra information about my, a potential condition that I don’t have or I do 
have.”’ (CP1)
Other hcPs
Patients spoke about utilising other HCPs, for instance, nurses or opticians who may be more accessible 
than GPs and less costly, yet perceived as more trustworthy than pharmacists. Nurse practitioners with 
a clinical interpretive ability were identified as being equally as expensive as CPs:
‘The reason I mentioned [Opticians X] is that they’ve extended what they do into hearing, and 
they do employ professionally qualified people obviously, in both of those areas. I think I trust 
what they are doing more than the retailer.’ (PT21)
‘We are more expensive than some nurses, but I think the nurses who feel competent 




The majority of patients spoke favourably about the relaxed environment within the consultation. 
Participants felt free from anxiety and 'mental block', which could occur with traditional health check- ups:
‘… went into the hospital having my pre- tests and they took my blood pressure, and said, “go 
on”, it was rocketingly sky high. And then referred back to my GP, GP said, “I suspect this was 
the scenario”, took my blood pressure and said, “it’s perfectly ok.” And, you know, went in for 
this … and there’s no anxiety, the difference that you get in the recording is huge. So, we walked 
away actually feeling quite satisfied.' (PT14)
However, a few patients, GPS, and one pharmacist complained about the co- running of screening 
with busy influenza vaccination clinics, which prevented CPs from providing comprehensive pre- 
appointment information:
‘Flu clinics are just busy and people are in a big queue … They are coming in and out quickly so 
to give them a bit of advanced warning or literature might be good.’ (GPS5)
Pharmacists identified that practice culture and infrastructure influenced how effectively the service 
was integrated:
‘One of the health centres was less welcoming and less set up for us to be there, um, the other 
one was much more accommodating and although you were made to feel quite welcome when 
we were there outside of the vaccination clinics I felt a little bit more like I was, just kind of 
visiting [laughs] rather than part of the scheme … And the [Town A] one was again a little bit ad 
hoc and the room we had wasn’t ideal.’ (CP4)
Patients debated the ongoing staff shortages, convoluted referral system, and excessively long 
appointment waiting times, which made general practice widely inaccessible:
‘This was early December, I’m still waiting for it. Every time I phone up, well the first time I 
phoned up, they said, “we are full for the next 3 weeks,” which took me to when I was going 
on holiday. And I phoned them when I came back, and oh yes, and they couldn’t, their diary 
wouldn’t run that far ahead.’ (PT8)
community pharmacy
Community pharmacies were considered to be more accessible than general practice surgeries, making 
AF screening in this setting a viable alternative. One participant argued that a close relationship with 
a local community pharmacist may be more beneficial to their health than engagement with HCPs at 
the surgery:
  9 of 13
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‘And I think that if you build up a relationship with the local pharmacist, you are going to be in a 
more stable condition than visiting a panel practice which I think a lot of us are, when you rarely 
see the same doctor two days running or two visits running I should say. And they spend half of 
their 10- minute slot reading your notes and then they say, “well time’s up, thank you very much, 
next patient, please.”’ (PT5)
Despite community pharmacy’s accessibility, participants viewed pharmacies as lacking clinical 
infrastructure or physical space to conduct AF screening consultations. A few patients were concerned 
about community pharmacy’s commercial nature and their confidentiality:
‘The one thing psychologically against going to pharmacist is that basically, my one is in 
Pharmacy V [large pharmacy chain] or there’s one near the surgery, they are like shops. You 
don’t think, “oh, well if they ask me to do something, you know, is it going to be here in front of 
people buying their soap?"’ (PT8)
Apart from space considerations, some participants doubted that a typical community pharmacy 
had sufficient staff to facilitate public health initiatives in addition to their traditional supply function:
‘It wouldn’t work because of CP2’s point, is that even with accuracy checking technicians, you 
still need a screening of the prescription.’ (CP4)
The waiting areas of general practice were thought to provide HCPs with enough time to approach 
eligible patients in contrast to the busy community pharmacy environment:
‘If you were to do it in a local pharmacy, how would you identify people that you wanted? 
Because our pharmacy is very busy. People come in there all the time whereas if you were at the 
surgery, there’s people sitting and waiting and you can sort of observe the type of person you’re 
looking for perhaps.’ (PT3)
Discussion
Summary
Facilitators and barriers to novel AF screening services emerged from interviews with three stakeholder 
groups, predominantly within five TDF domains. Patients and staff highlighted the necessity to raise 
public awareness of AF- related risks and the clinical roles of pharmacists. Most interviewees were 
fascinated by single- lead ECG technology, and identified pharmacists as qualified but underutilised 
practitioners who could increase GP capacity at the time of a workforce crisis. Pharmacists welcomed 
the evolution of a new clinical role focusing on their advisory and educational skills. Despite superior 
accessibility of community pharmacy, patients preferred pharmacist- led AF screening in general 
practice surgeries, which were viewed as more established and less commercialised. All stakeholder 
groups agreed on the need to develop AF screening programmes prioritising at- risk individuals, such 
as those attending diabetes or hypertension clinics, or those residing in care homes.
Strengths and limitations
The method of focus group discussion provided a key advantage of interaction between the members 
of each stakeholder cohort. Patients were demographically representative of the PDAF study sample 
and displayed both concordant and diverging opinions on different aspects of service design. This 
study also benefitted from the group interview with GPS, the majority of whom were not directly 
involved in PDAF and were, therefore, able to provide impartial views.
The convenience sampling strategy may have overlooked those with limited interest in or access to 
healthcare initiatives. Most patients were also registered at a single surgery, and it is possible that their 
opinions influenced the themes derived, despite the facilitators’ attempts to take the perspectives of all 
participants into account. Lack of GP or senior manager participation in this study was another limitation, 
although it may have had a positive impact by minimising the influence of any hierarchical relationships.36
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Comparison with existing literature
Research studies in Australia have identified lack of public awareness of AF as the primary barrier to 
patient engagement in screening initiatives.13,22 Stakeholder perspectives presented here conformed 
with such findings. The combined views of patients and staff suggested that this barrier may only 
be overcome through the delivery of a structured, multifaceted programme, which resembled 
the 'layered' approaches by Lowres et al21 or Sabater- Hernández et al.22 The closer engagement 
of stakeholders could be encouraged through central leadership of GPs, practice managers, and 
commissioners, perhaps by allocating a responsible person previously referred to as a 'designated 
champion'.14
As expected,22 despite their interest in technology, patients were unenthusiastic about self- 
monitoring, praising the advisory value of pharmacists. For example, CPs may be able to reassure 
the patients with suspected AF or inconclusive diagnoses who could otherwise experience anxiety 
after a false positive test result at home.37 Practice nurses were considered a possible substitute 
to pharmacists and had previously demonstrated a high degree of confidence in carrying out AF 
screening.13,14 In a recent survey however, only 25% of nurse practitioners felt qualified to make 
decisions about AF management post- ECG.16 This is an area where CPs may use their medicines 
expertise, for instance, by developing one- stop AF screening and anticoagulation clinics within an 
established clinician- referral pathway.38,39
Similar to discussion by Orchard et al,14 the combination of AF screening and influenza vaccinations 
during the PDAF initiative may have engaged the ‘annual’ surgery visitors. Nevertheless, this group 
appeared to be the proactive, lower- risk ‘healthy volunteers’40 rather than the hard- to- reach, at- risk 
group such as care home residents.41,42 As an alternative, an ‘MOT’ screening package was proposed 
to target AF and related comorbidities of diabetes and hypertension, focusing on at- risk patients; a 
variation of the community pharmacist- led programme by Twigg et al.20
During the present study, interviewees were not eager to pursue AF screening within the 'shop' 
environment of community pharmacies and preferred the less accessible but more 'trusted' general 
practice surgeries. Interestingly, public perception was altered on pharmacists' integration within 
surgery environments, where they were regarded as competent HCPs. This environment–identity 
interaction is not uncommon, but appears to fade over time as pharmacists transition into the new 
practice role.43,44
Implications for research and practice
Practice- based CPs provide a wide range of clinical services45 and have become an integral part of the 
NHS Long- term Plan.18,25 Data presented here suggests that, as experts of medicines and public health, 
these professionals are ideally placed to conduct AF screening, to educate the public and to address 
medicines- related concerns as part of a cardiovascular ‘MOT’ service. It is likely that the specification of 
this holistic service will evolve from the government’s cardiovascular agenda,8 while targeting medicines 
optimisation among those at risk of AF, such as patients with type 2 diabetes.46
Regardless of the approach, it should make use of evidence generated through ongoing national 
AF screening efforts9 and the additional general practice pharmacy workforce, which had been 
demonstrated to produce cost- savings and to free up GPs to focus on more complex patients.23,47,48 
Stakeholders interviewed here suggested that pharmacists might help utilise the strengths of existing 
practice infrastructure and clinical expertise, while addressing the major barrier of inaccessibility. 
Future AF screening guidelines may also wish to consider the favourable profile of single- lead ECG 
devices highlighted by both patients and providers.
A separate evaluation of PDAF screening results and cost- effectiveness is expected to provide further 
evidence to support the qualitative perspectives of a novel pharmacist- led service discussed here. A 
future research programme will also aim to capture the views of GPs by conducting semi- structured 
interviews with those who may or may not be involved in the delivery of AF screening services.
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